Rituximab targets all CD20 expressing B-cells, including precursor B cells and mature and memory B cells, whereas it does not interact with CD20-negative early pre-B cells and terminally differentiated plasma cells

Rituximab targets all CD20 expressing B-cells, including precursor B cells and mature and memory B cells, whereas it does not interact with CD20-negative early pre-B cells and terminally differentiated plasma cells. cell-mediated skin autoimmune disorders, including autoimmune blistering skin diseases (2, 3). Rituximab targets all CD20 expressing B-cells, including Oridonin (Isodonol) precursor B cells and …
Continue reading Rituximab targets all CD20 expressing B-cells, including precursor B cells and mature and memory B cells, whereas it does not interact with CD20-negative early pre-B cells and terminally differentiated plasma cells

Apart from non-coding RNA, m6A RNA methylation is another crucial chemical modification discovered in mRNA and non-coding RNA in eukaryotic cells,188,189 the process of which is dynamically regulated by a series of writers, readers, and erasers

Apart from non-coding RNA, m6A RNA methylation is another crucial chemical modification discovered in mRNA and non-coding RNA in eukaryotic cells,188,189 the process of which is dynamically regulated by a series of writers, readers, and erasers.190 In melanoma, the expression of m6A demethylase FTO is significantly upregulated to contribute to not only tumorigenicity but also …
Continue reading Apart from non-coding RNA, m6A RNA methylation is another crucial chemical modification discovered in mRNA and non-coding RNA in eukaryotic cells,188,189 the process of which is dynamically regulated by a series of writers, readers, and erasers